Sorafenib Market Report 2026

Sorafenib Market Overview

• Sorafenib market size has reached to $1.29 billion in 2025 • Expected to grow to $1.56 billion in 2030 at a compound annual growth rate (CAGR) of 3.9% • Growth Driver: Rising Cancer Prevalence Fuels Growth In The Sorafenib Market An Overview Of Current Trends And Future Projections • North America was the largest region in 2025.

What Is Covered Under Sorafenib Market?

Sorafenib is a medication used primarily in the treatment of certain types of cancer. It is classified as a targeted therapy drug and works by inhibiting specific enzymes and proteins involved in cancer cell growth and tumor blood vessel formation. The main product types of sorafenib are patented drugs and generic drugs. Patented drugs are medications that are protected by intellectual property rights, typically a patent granted to the company or individual who discovered or developed the drug. These are distributed through various distribution channels such as hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. These are used in various applications such as kidney cancer, liver cancer, and thyroid cancer.

What Is The Sorafenib Market Growth Forecast?

The sorafenib market size is expected to see steady growth in the next few years. It will grow to $1.56 billion in 2030 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to growth in generic oncology drugs, increasing cancer diagnosis rates, focus on cost-effective cancer treatments, expansion of oncology care infrastructure, combination therapy research. Major trends in the forecast period include growing use of targeted cancer therapies, expansion of generic sorafenib products, rising adoption in liver and kidney cancer treatment, combination therapy approaches in oncology, improved access to oncology drugs in emerging markets.

Global Sorafenib Market Segmentation

1) By Product: Patented Drugs, Generic Drugs 2) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies 3) By Application: Kidney Cancer, Liver Cancer, Thyroid Cancer Subsegments: 1) By Patented Drugs: Nexavar 2) By Generic Drugs: Generic Sorafenib Tosylate, Other Generic Variants

What Are The Drivers Of The Sorafenib Market?

The increasing prevalence of cancer is expected to propel the growth of the sorafenib market going forward. Cancer refers to a group of diseases characterized by uncontrolled cell growth with the ability to invade surrounding tissues and spread to other parts of the body. The prevalence of cancer is rising due to aging populations, lifestyle factors, environmental exposures, and improved diagnostic capabilities that lead to higher detection rates. The sorafenib market supports cancer management by providing a multi-kinase inhibitor that targets tumor growth and angiogenesis pathways, offering an effective treatment option for advanced renal cell carcinoma and hepatocellular carcinoma. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based biomedical information resource, an estimated 1,958,310 new cancer cases and 609,820 cancer deaths occurred in the United States in 2023. Therefore, the increasing prevalence of cancer is driving the growth of the sorafenib industry. The rising healthcare expenditure is expected to propel the growth of the sorafenib market going forward. Healthcare expenditure refers to the total amount of money spent on healthcare services, treatments, equipment, and public health activities to maintain and improve people’s health. Rising healthcare expenditure is primarily due to increasing chronic disease prevalence, which drives higher demand for long-term treatments, frequent medical visits, and costly ongoing care. Healthcare expenditure supports the uptake of sorafenib by enabling broader access to advanced oncology treatments, funding early diagnosis and specialist care, and improving patient affordability for high-cost targeted therapies. For instance, in May 2024, according to the Office of National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, the rising healthcare expenditure is driving the growth of the sorafenib industry.

Key Players In The Global Sorafenib Market

Major companies operating in the sorafenib market are Bayer AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Natco Pharma, Hikma Pharmaceuticals PLC, Beacon Pharmaceuticals Ltd., Hetero Healthcare Ltd., Aprazer Healthcare Private Limited, Wellona Pharma, Anant Pharmaceuticals Pvt. Ltd., Intelicure Lifescience, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Accord Healthcare, Sandoz, MSN Laboratories, Alvogen

What Are Latest Mergers And Acquisitions In The Sorafenib Market?

In June 2024, Lotus Pharmaceuticals Co. Ltd., a Taiwan-based company engaged in manufacturing and selling generic drugs, acquired Teva Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition strengthens Lotus Pharmaceuticals’ position in the global generics market by integrating Teva’s extensive pharmaceutical portfolio and operational expertise. It further enhances Lotus’s market reach and product diversification by adding Teva’s broad capabilities in oncology, including the manufacturing of sorafenib tablets. Teva Pharmaceutical Industries Ltd. is an Israel-based pharmaceutical company that manufactures sorafenib tablets.

Regional Insights

North America was the largest region in the sorafenib market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Sorafenib Market?

The sorafenib market consists of sales of nexavar, and sorafenib combination tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sorafenib Market Report 2026?

The sorafenib market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sorafenib industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.